Key facts
- This page summarizes James Alecxih's Form 3 filing for TriSalus Life Sciences, Inc. (TLSI).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Aug 2023, 19:02.
James Alecxih - 10 Aug 2023 Form 3 Insider Report for TriSalus Life Sciences, Inc. (TLSI)
- Reporting relationship
- President, Device Technology
- Issuer ticker
- TLSI
- Reported as of
- 10 Aug 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Sean Murphy, Attorney-in-Fact for James Alecxih
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
James Alecxih filed Form 3 for TriSalus Life Sciences, Inc. (TLSI) on 14 Aug 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLSI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 94,754
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLSI
holding
Derivative
Employee Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 10 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 94,754
- Exercise price
- $10.30
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).
Footnote F2
Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 20, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Footnote F3
Twenty-five percent of the shares subject to the option vest on February 20, 2024, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.